Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Endocrinology | Family Medicine | Geriatrics | Internal Medicine | Nursing | Orthopedics | Pharmacy | Journal

Back to Journal Articles

Once-Yearly Zoledronic Acid Benefits Men With Osteoporosis

Last Updated: October 31, 2012.

 

Significant drop in risk of new vertebral fractures, increased bone density, lower bone turnover

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a study published in the Nov. 1 issue of the New England Journal of Medicine.

WEDNESDAY, Oct. 31 (HealthDay News) -- For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a study published in the Nov. 1 issue of the New England Journal of Medicine.

Steven Boonen, M.D., Ph.D., from the Katholieke Universiteit Leuven in Belgium, and colleagues investigated the effect of zoledronic acid on fracture risk in a multicenter, randomized trial involving 1,199 men with osteoporosis. Participants, aged 50 to 85 years, were randomly allocated to receive an intravenous infusion of either zoledronic acid or placebo at baseline and at 12 months. All participants received calcium and vitamin D each day and were followed for 24 months.

The researchers found that, over the 24-month period, the rate of any new morphometric vertebral fractures was 1.6 percent in the zoledronic acid group and 4.9 percent in the placebo group (relative risk, 0.33; P = 0.002). Men who received zoledronic acid had significantly fewer moderate-to-severe vertebral fractures and significantly less height loss compared with those receiving placebo. Fewer men in the zoledronic acid group had clinical vertebral or non-vertebral fractures, although due to the small number of fractures, this difference did not reach significance. Men who received zoledronic acid had higher bone mineral density and lower levels of bone-turnover markers.

"In conclusion, our prospective study that assessed fractures as the primary end point in men with osteoporosis showed that, over a two-year period, a once-yearly infusion of zoledronic acid at a dose of 5 mg was associated with a significant decrease in the risk of new vertebral fractures," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which funded the study and manufactures zoledronic acid.

Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Single Topical Ivermectin Head Lice Treatment Very Effective Next: American College of Chest Physicians, Oct. 20-25, 2012

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.